-
公开(公告)号：US20220411413A1
公开(公告)日：2022-12-29
申请号：US17872680
申请日：2022-07-25
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: C07D405/14 , C07D209/46 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D401/06 , C07D405/04 , A61K31/4035 , A61K31/4155 , A61K31/4439 , A61K31/13 , A61K31/325 , A61K31/445 , A61K31/55 , A61K31/045 , A61K31/4406
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.-
公开(公告)号：US20200255439A1
公开(公告)日：2020-08-13
申请号：US16651840
申请日：2018-09-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Makoto KAMATA , Hideyuki SUGIYAMA , Minoru NAKAMURA , Masataka MURAKAMI , Shuhei IKEDA , Tomohiro OKAWA , Hidekazu TOKUHARA
IPC: C07D487/10 , A61P25/28 , A61K9/48 , A61K9/20
Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
-
公开(公告)号：US20190241547A1
公开(公告)日：2019-08-08
申请号：US16209349
申请日：2018-12-04
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: C07D405/14 , C07D209/46 , A61K31/4439 , A61K31/4406 , A61K31/045 , A61K31/55 , A61K31/445 , A61K31/325 , A61K31/13 , C07D401/06 , A61K31/4155 , A61K31/4035 , C07D403/10 , C07D403/04 , C07D401/14 , C07D401/10 , C07D405/04
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20170100373A1
公开(公告)日：2017-04-13
申请号：US15388834
申请日：2016-12-22
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: A61K31/4035
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20170027921A1
公开(公告)日：2017-02-02
申请号：US15291769
申请日：2016-10-12
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: A61K31/4439 , A61K31/4155 , A61K31/4035
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
Abstract translation: 其中每个符号如说明书中所述或其盐。
-
Patent Agency Ranking
公开(公告)号：US20160376244A1
公开(公告)日：2016-12-29
申请号：US15190642
申请日：2016-06-23
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC: C07D265/22 , C07D413/06 , C07D491/107 , C07D413/04 , C07F7/02 , C07D471/04 , C07D413/14 , C07D413/10
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
Abstract translation: 其中每个符号如所附的说明中所定义。
-
公开(公告)号：US20230134307A1
公开(公告)日：2023-05-04
申请号：US18087302
申请日：2022-12-22
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Shuhei IKEDA , Makoto KAMATA , Yuya OGURO , Jumpei AIDA , Taisuke TAWARAISHI , Takeshi WAKABAYASHI , Norio OYABU , Atsuko OCHIDA , Kouichi IWANAGA , Satoshi YAMAMOTO , Masataka MURAKAMI , Minoru NAKAMURA , Fumie YAMAGUCHI , Takafumi YUKAWA
IPC: C07D207/263 , A61P25/18 , C07D401/06
Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
-
公开(公告)号：US20190300536A1
公开(公告)日：2019-10-03
申请号：US16366710
申请日：2019-03-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Yuya OGURO , Shigemitsu MATSUMOTO , Takeshi WAKABAYASHI , Norihito TOKUNAGA , Taku KAMEI , Mitsuhiro ITO , Satoshi MIKAMI , Masaki SETO , Shinji MORIMOTO , Shinji NAKAMURA , Sachie TAKASHIMA , Masataka MURAKAMI , Masaki DAINI , Makoto KAMATA , Minoru NAKAMURA , Yasufumi WADA , Hiroyuki KAKEI , Kazuaki TAKAMI , Taisuke TAWARAISHI , Jumpei AIDA , Kouichi IWANAGA , Satoshi YAMAMOTO
IPC: C07D487/04 , C07D471/04 , A61K9/20 , A61K9/48
Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
-
29.发明申请公开(公告)号：US20190248776A1
公开(公告)日：2019-08-15
申请号：US16394762
申请日：2019-04-25
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC: C07D413/14 , C07D491/107 , C07D471/04 , C07D417/06 , C07D413/10 , C07D413/06 , C07D265/22 , C07F7/02 , C07D413/04 , C07F7/08 , A61P25/28 , C07D417/10
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号：US20180362516A1
公开(公告)日：2018-12-20
申请号：US16113635
申请日：2018-08-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Takuto KOJIMA
IPC: C07D413/14 , C07D413/06 , C07D471/04 , C07D491/107 , C07D413/04 , C07F7/02 , C07D417/06 , C07D265/22 , C07F7/08 , C07D417/10 , A61P25/28 , C07D413/10
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.038 seconds)
